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Background: Genetically modified cells have been shown to be one of the most effective tumor vaccine strategies.
However, in many cases, such as in melanoma, induction of a potent immune responses against the disease still
remains a major challenge. Thus, novel strategies to reinforce tumor vaccine efficacy are needed. Using microRNA
(miR) and Zinc-finger E-box binding homeobox (ZEB) have received much attention for potentially regulating tumor
progression. To elicit a potent antitumor efficacy against melanoma, we used tumor vaccine in combination with
miR200c overexpression or ZEB1 knockdown to assess the efficacy of treatment of murine melanoma.
Methods: B16F10 cell vaccine expressing interleukin 21 (IL-21) in the glycosylpho- sphatidylinositol (GPI)-anchored
form (B16F10/GPI-IL-21) were developed. The vaccine was immunized into mice challenged by B16F10 cells or
B16F10 cells stably transduced with lentiviral-miR200c (B16F10/miR200c) or transfected with the ZEB1-shRNA
recombinant (B16F10/shZEB1) or the B16F10/GPI-IL-21 vaccine. The immune responses, tumorigenicity and lung
metastasis in mice were evaluated, respectively.
Results: The vaccination with B16F10/GPI-IL-21 markedly increased the serum cytokine levels of IFN-γ, TNF-α, IL-4
and decreased TGF-β level as well as augmented the cytotoxicity of splenocytes in immunized mice compared
with control mice. In addition, the tumor vaccine B16F10/GPI-IL-21 significantly inhibited the tumor growth and
reduced counts of lung metastases in mice challenged by B16F10/GPI-IL-21, B16F10/shZEB1 and B16F10/miR200c
respectively compared with the control mice challenged by B16F10 cells. The efficacy mechanisms may involve in
reinforcing immune responses, increasing expression of miR200c, E-cadherin and SMAD-7 and decreasing
expression of TGF-β, ZEB1, Vimentin and N-cadherin in tumor tissues from the immunized mice.
Conclusions: These results indicate that the tumor vaccine B16F10/GPI-IL-21 in combination with miR200c
overexpression or ZEB1 knockdown effectively inhibited melanoma growth and metastasis a murine model. Such a
strategy may, therefore, be used for the clinical trials.
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Melanoma is malignant and is one of the deadliest forms
of skin cancer and its incidence is expected to rise over
the next two decades. Despite significant progress in
melanoma research having been made over the years,
there are no effective therapies for advanced melanoma
at present [1,2]. A growing body of literature shows that
the immunotherapeutic approaches to use the immune
system against cancer have focused on therapeutic vac-
cines that intended to specifically initiate or amplify a
host response against evolving tumor cells [3-5].
Glycosylphosphatidylinositol (GPI) is a posttranslational
added lipid anchor and GPI-anchored membrane cyto-
kines have been shown to play an important role in host
immune responses against tumor cells [6]. Interleukin
(IL)-21 is a T cell-derived cytokine that is involved in T
and NK cell activation in the tumor vaccine approaches.
Studies have showed that IL-21 is widely applied to signifi-
cantly augment antitumor immunity in multiple murine
tumor models and clinical trials [7-9], and to generate
considerable research interest in understanding its mode
of action. Our previous study showed that administering
whole tumor cell vaccine expressing IL-21 in the GPI-
anchored form (B16F10/GPI-IL-21) induced protective
anti-melanoma immunity in a B16F10 cell transplantable
mouse model. However, an anti-melanoma efficacy failed
to completely induce objective tumor shrinkage because
the measurable and metastatic tumors were developed in
some B16F10 melanoma-bearing mice, highlighting the
need for using combination and alternative strategies
[10,11]. More recent approaches have centered on a series
of molecules known as potentially regulating tumor pro-
gression such as microRNA-200c (miR200c) [12] and zinc
finger E-box binding homeobox 1 (ZEB1) [13], which have
provided proofs that overexpression of miR200c or knock-
down of ZEB1 could repress tumor ‘epithelial to mesen-
chymal transition’ (EMT) program that activates cellular
mobility, subsequent tumor metastasis [14-16].
Recent researches have demonstrated that ZEB1 has an
important regulatory role on the malignant tumor progres-
sion through regulating cell cycle, apoptosis, senescence, in-
vasion, metastasis and mesenchymal angiogenesis [12,17].
Our previous studies indicated that the disturbance of
EMT-miR-200c-ZEB1 feedback loop promoted the melan-
oma proliferation and invasive metastasis [16], and that the
miR-200c overexpression in CD44+CD133+B16F10 cells
markedly inhibited the cell proliferation and invasion ability
in vitro as well as tumorigenicity in vivo [18]. It is known
that the rapid progression of primary melanomas to locally
invasive and metastatic other sites is a major obstacle for
therapeutic interventions of melanoma patients. On the
basis of these findings, we speculate that the EMT-inducer
ZEB1 may support tumor metastasis in B16F10 melanoma-
bearing mouse model by promoting tumor cell mobilityand dissemination, and that antitumor immune responses
induced by tumor vaccine B16F10/GPI-IL-21 might result
in tumor cell apoptosis and inhibit tumor growth but do
not block the EMT of B16F10 cells or metastasis in mice.
In this regard, we used the novel strategy that the tumor
vaccine B16F10/GPI-IL-21 was combined with overexpres-
sion of miR200c or knockdown of ZEB1 to evaluate the
synergitic efficacy of treatment of murine melanoma, and
to attempt to investigate the molecular mechanisms of mel-
anoma metastasis in the present study.
Here, we show that the tumor vaccine B16F10/GPI-
IL-21 in combination with potentially synergistic active
therapies, such as either miR200c overexpression or ZEB1
knockdown, significantly represses tumor growth, blocks
melanoma EMT program and inhibits tumor metastasis
in a murine melanoma model.
Materials and methods
Animals
C57BL/6 mice between 5–6 weeks of age were obtained
from the Yang Zhou University of China (license num-
ber: SCXK, Jiangsu province of China, 2007–0001). All
mice were housed under the specified pathogen-free
condition and the experiments were performed in com-
pliance with the guidelines of the Animal Research Eth-
ics Board of Southeast University.
Cells
B16F10 murine melanoma cell line is syngeneic in C57BL/
6 mice and Human embryonic kidney (HEK) 293 T cells
purchased from the Cellular Institute in Shanghai, China.
B16F10 cells were cultured at 37°C in 5% CO2 atmosphere
in RPMI 1640 supplemented with 10% fetal bovine serum
(FBS, Gibco BRL, USA) that contained 100U/ml penicillin
G sodium and 100 μg/ml streptomycin. HEK 293 T cells
were cultured in Dulbecco’s Modified Eagle Medium
(DMEM, Invitrogen, NY, USA) plus 10% FBS, 2 mmol/
L L-glutamine, 100 U/ml penicillin, and 100 μg/ml strepto-
mycin at 37°C in a humidified 5% CO2 atmosphere.
Short hairpin RNA sequence design, construction of
shRNA1 targeting ZEB1 gene and screen of clones stably
transfected with shRNA1
Short hairpin RNA sequence of mouse ZEB1 was de-
signed based on the ZEB1 mRNA ID (GenBank NO.
NM_011546.3) using the siDESIGN design software
(Dharmacon, http://www.thermoscientificbio.com/design-
center/) and Block-iTTM RNAi Designer (Invitrogen,
Grand island, NY) as well as BLAST (http://www.ncbi.
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square frames in nucleotide sequences contain the 9 nu-
cleotide spacers, respectively. The underlined sequences
contain BglII and HindIII enzyme cut sites. The primers
were synthesized by Gene and Technology of China in
Shanghai. A pSUPER-EGFP1 (enhanced green fluorescent
protein 1) vector was used to construct recombinant
pSUPER-EGFP1-ZEB1-shRNA1 as previously described
[19]. A pSUPER- EGFP1-scrambled shRNA (Scramble)
was used as a negative control. These recombinants were
verified by the analyses of endonuclease digestion and se-
quencing. B16F10 cells were transfected with either the
ZEB1-shRNAs or the Scramble-shRNA by using Lipofec-
tamine™ 2000 reagent (Invitrogen, USA) following the
manufacturer’s protocol. After an antibiotic selection with
800 μg/ml G418 (Clontech, CA), the ZEB1-shRNA1-
B16F10 clones were isolated from the G418 resistant cells
for each transfection pooled and expanded into cell
lines and designated ‘B16F10/shZEB1’. ZEB1 expression
was detected by quantitative-PCR and western blotting,
respectively [20].
Transduction of lentivirus miR-200c and production of
stable expression clones
To generate the miR-200c expression lentivirus vector,
we amplified an insert (full-length mouse miR-200c) by
PCR from B16F10 cell DNA. The lentivirus miR-200c
was produced from the transient transfection of the
HEK293T cells with pHAGE-CMV-miR-200c-IZsGreen,
psPAX2, and pMD2.G plasmid DNAs plus Lipofectamine
2000 (Invitrogen, USA) according to the manufacturer’s
protocol. Forty-eight hours after the cotransfection, the
lentivirus- bearing supernatants were collected and passed
through a 0.45-mm filter. B16F10 cells were infected with
the pHAGE-CMV-miR-200c-IzsGreen lentivirus, and were
selected by the IzsGreen expression [21]. The stable ex-
pression clones were selected by limiting the dilution assay
and designated‘B16F10/miR200c’ [22].
Quantitative-PCR assay
Quantitative-PCR analysis was performed on an ABI
step one plus real-time system (Applied Biosystems).
The comparative Ct (ΔΔCt) method was used to deter-
mine the expression fold change [12]. Total cellular
RNA was isolated from each sample by using a Qiagen
RNeasy Kit (Qiagen, Valencia, CA). One microgram of
total RNA from each sample was subjected to cDNA
synthesis using the Superscript III reverse transcriptase
(Invitrogen). cDNAs were amplified by PCR with
primers as follows: miR-200c (sense, 5′-GAAGATCTG
GAGCAGG AGATCTGCCGCTTC-3; reverse, GGAA
TTCAGAGCCACCCTTAACTCGG); ZEB1(sense, 5′-T
GAGCACACAGGTAAGAGGCC-3′; reverse, 5′-GGC
TTTTCCCCAGAGTGCA-3′); β-actin (sense, 5′-GCCCTGAGGCTCTTTTCCA −3′; reverse, 5′-TTACGG
ATGTCAACGTC A-3′); U6 (sense, 5′-CTCGCTTC
GGCAGCACATAGG-3′; reverse, 5′-AACGCTTCAC
GAA TTTGCG TAGGAG-3′); URP Universal Reverse
Primer, 5′-CCGGCAGGGTCCGAGGT-3′.
Western blot
1 × 106 different cells were collected and lyzed in the
protein extraction buffer (Novagen, Madison, WI, USA)
by following the manufacturer’s protocol. 12% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis was
performed and the proteins (10 μg/lane) were transferred
onto a PVDF membrane blocked with 4% dry milk in Tris-
buffered saline with Tween-20 for 1 h at 20°C, and then in-
cubated with the goat anti-mouse IL-21 (I-18, Santa Cruz
Biotechnology Company, Santa Cruz, CA, USA), rabbit
anti-mouse ZEB1, Vimentin, E-cadherin, N-cadherin, TGF-
βand SMAD-7 (Bioworld Technology, Dublin, OH, USA),
respectively for overnight at 4°C. The membrane was
rinsed for 5 min with an antibody wash solution for 3 times
before adding goat anti-rabbit or rabbit anti-goat fluores-
cence secondary antibody for 1 h at 20°C. Immunoreactive
bands were detected by Odyssey scanning instrument (LI-
COR Odyssey Imaging System, USA) [16].
Animal experiment
C57BL/6 mice were initially immunized subcutaneous (s.c.)
with 1 × 106 B16F10/GPI-IL-21 tumor vaccine inactivated
with 2 μg/ml mitoxantrone in a mouse’s right flank, and
the immunization was performed three times at a week
interval [16]. The B16F10/GPI-IL-21 tumor vaccine was
developed as previously described [10] and stored in our
Lab. About 10 days after the final immunization, the
mice were randomly divided into four groups: the
B16F10/wild type (WT) group; B16F10/shZEB1 group;
B16F10/miR200 group and B16F10/GPI-IL-21 group.
Finally, all mice were challenged s.c. with 2 × 105 above-
mentioned different B16F10 cells. Six mice/group were
used in the study, and the experiment was repeated
twice. Tumor growth was monitored every three day by
measuring two perpendicular tumor diameters using
calipers, and then the counts of lung metastases [15]
were also examined after mice were sacrificed.
Immunosorbent assay
Immunosorbent assay (ELISA) for detecting IFN-γ, TNF-
α, IL-4 and TGF-β was performed by following the Kit’s
protocol (eBioscience, CA). The Kit is suitable for detec-
tion of samples including cell culture supernatant and
serum, and the sensitivity of Kit is 5.3 pg/mL [23,24].
Assay of splenocyte cytotoxicity
Ten days after the final immunization, 5 × 106 spleno-
cytes were harvested from the mice immunized with the
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used for effector cells that were labeled with 0.5 mM 5-
(and 6)-carboxy-fluorescein diacetate succinimidyl ester
(CFSE; 20 μg/ml) at 37°C for 15 min. The labeled sple-
nocytes were washed twice in PBS containing 5% FBS to
sequester any free CFSE. The CFSE-labeled effector cells
were seeded with a constant number of B16F10 target
cells in a 96-well plate at 25:1 ratios of effector cells to
target cells (E:T). The cytotoxicity assay was performed
in triplicate. Flow cytometric CFSE/7-AAD cytotoxicity
assay was analyzed by Flow Cytometry (FCM, BD com-
pany, USA) [11,25].
Immunohistochemistry
4 μm-thin formalin fixed and paraffin-embedded slides
were incubated with the rabbit anti-mouse ZEB1, Vimen-
tin, E-cadherin, N-cadherin, TGF-βand SMAD-7 (Bioworld
Technology, Dublin, OH, USA), respectively overnight at
4°C. Antibody concentration was 1:1000. The samples were
then labeled with horseradish peroxidase-conjugated strep-
tavidin (Invitrogen) and the chromogenic reaction that was
developed using Liquid DAB Substrate Pack according to
the manufacturer’s instructions. The stained cells from ran-
dom and non-overlapping fields were counted under a
magnification of × 400 [15,26].
Statistical analysis
Values of interest was presented as the mean plus or
minus standard deviation. Statistical comparisons were
performed using the Student’s t-test and Fisher/Chi-
square test methods. A P value of <0.05 was considered
statistically significant.
Results
Screen of transfected and transduced clones and
identification of expression of IL-21, miR-200c and ZEB1
in a different B16F10 cells
To develop B16F10/miR200c and B16F10/shZEB1, we first
constructed the miR-200c lentivirus vector and shZEB1 re-
combinant and then transduced and transfected them into
B16F10 cells, respectively, and finally the clones stably
transduced with miR-200c lentivirus vector or transfected
with shRNA1 recombinant were screened. Figures 1A-D
show the B16F10 cells and the B16F10/IL-21-GPI cells
were observed under a light microscope (left-panels) and
under a fluorescence microscope(right-panels), in which
the fluorescence is displayed on the surface of B16F10/IL-
21-GPI cells, and the nucleus with DAPI (Figure 1D), but
no green florescence on the surface of B16F10 cells in
(Figure 1C). This result suggested IL-21 was expressed on
the surface of B16F10/IL-21-GPI cells, which was further
confirmed by the result of western blot. IL-21 band was
found in B16F10/IL-21-GPI cells isolated from the G418
resistant cells as is shown in Figure 1E.The B16F10/shZEB1 cell clones (Figure 1F) and the
B16F10/miR200c cell clones (Figure 1J) were selected by
limiting dilution assay, and were observed under a light
microscope, and the same clones were observed under a
fluorescence microscope (Figure 1G and K). The results
suggested that the clones stably transfected with shRNA1
or stably infected with lentivirus miR-200c were success-
fully isolated from the B16F10 cells. After the endogenous
expression of miR-200c or ZEB1 in the B16F10 cells was
identified by RT-PCR (data not shown), we analyzed the
expression of miR-200c and ZEB1 in the transfected and
transduced B16F10 cells. It was found that the expression
of ZEB1 was higher in the B16F10 wild type (WT) cells
than in B16F10/shZEB1 cells, whereas the miR-200c ex-
pression was obviously increased in B16F10/ZEB1 cells
compared with B16F10 WT cells (Figure 1H and I).
Figure 1L indicates miR-200c expression is lower in the
B16F10 WT cells than in B16F10/miR-200c cells, whereas
the expression of ZEB1 was higher in the B16F10 WTcells
than in B16F10/ miR-200c cells (Figure 1L and M). These
molecular expression differences were statistically signifi-
cant as are shown in Figure 1.
Changes of serum cytokine levels and cytotoxicity of
splenocytes in the mice immunized with the tumor
vaccine B16F10/GPI-IL-21
To test the immune efficacy of the tumor vaccine
B16F10/GPI-IL-21 we first detected serum cytokine levels
in the immunized mice. Figures 2A-D indicate that com-
pared with mice immunized with the B16F10 cells, the
serum cytokine levels of IFN-γ, TNF-α and IL-4 were sig-
nificantly increased after the mice were immunized with
the tumor vaccine B16F10/GPI-IL-21, whereas the
serum TGF-β level was markedly decreased, which was
statistically significant (A-D). Next we analyzed the cel-
lular immune response in the immunized mice. It was
found that the cytotoxicity of splenocytes to B16F10 tar-
get cells at 25:1 ratio was notably enhanced (61±2.6%)
in mice immunized with the tumor vaccine B16F10/
GPI-IL-21 in contrast to mice immunized with the
B16F10 cells (23±2.8%), and the difference was statisti-
cally significant (P = 0.0003). These data suggested that
the tumor vaccine B16F10/GPI-IL-21 induced the mice
to generate a strong immune responses.
Tumor vaccine B16F10/GPI-IL-21 in combination with
miR200c overexpression or ZEB1 knockdown reduced
melanoma growth and metastasis
To augment therapeutic B16F10 melanoma efficacy by
tumor vaccine B16F10/ GPI-IL-21 in C57BL/6 mice, we
adopted a novel strategy that the tumor vaccine B16F10/
GPI-IL-21 were combined with miR200c overexpression
or ZEB1 knockdown in B16F10 cells in current antitumor
experiment. Figure 3A gives the images of mice challenged
Figure 1 Observation of the different clones and detection of expression of IL-21, miR-200c and ZEB1 in B16F10 cells. (A-D, F, G, J, K)
Morphological photos of B16F10 wild type (WT) clones, B16F10/GPI-IL-21 clones, B16F10/shZEB1 clones and B16F10/miR200c clones in order. The
clones in left side were observed under a light microscrope, and the clones in right side were observed under a fluorescence microscrope.
Magnification 400 × (A-D), and magnification 100 × (F, G, J, K). (D) The fluorescence on the surface of B16F10/GPI-IL-21 cells, but no fluorescence
on the surface of B16F10 WT cells (B). (E) The positive band IL-21 in lane 2 in B16F10/GPI-IL-21 cells detected by western blot. (H, I) The
expression of ZEB1 RNA and miR200c in shZEB1 stably transfected B16F10/shZEB1 cells and B16F10 WT cells detected by qRT-PCR. (L, M) The
expression of miR200c and ZEB1 in lentivirus miR-200c stably transduced B16F10/miR200c cells and B16F10 WT cells detected by qRT-PCR.
Figure 2 Tumor vaccine B16F10/GPI-IL-21 induced immune responses in mice. (A-D) Serum cytokine levels of IFN-γ, TNF-α, IL-4 and TGF-β
were respectively detected by ELIAS in the B16F10/GPI-IL-21 vaccination of mice. (E) The splenocyte cytotoxicity to B16F10 cells at 25:1 ratio was
analyzed by FCM in the immunized mice. (F) The analysis of splenocyte cytotoxicity.
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Figure 3 B16F10/GPI-IL-21 vaccination of C57BL/6 mice in combination with either miR200c overexpression or ZEB1 knockdown
against B16F10 melanoma. (A) Images of the B16F10/ GPI-IL-21 vaccine immunized mice at 40 days after the mice were challenged by the
different B16F10 cells. (B-D) Tumor volumes, tumor free mice and melanoma bearing mouse survival. (E) Images of metastasis nodules in murine
lung. (F) The statistical analysis of metastatic tumor nodules. (G) The pathological changes in murine lung from the immunized mice that were
challenged by the different B16F10 cells. (H) The statistical analysis of relative lung metastatic rates.
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mice were immunized with the tumor vaccine B16F10/
GPI-IL-21 three times. We found that 3 of the 6 immu-
nized mice developed tumors on Day 15, Day 18 and Day21, respectively after the 6 mice were challenged by the
B16F10 cells. The immunized mice challenged by the
inactivated B16F10/GPI-IL-21tumor vaccine also devel-
oped tumors on Day 18, Day 21 and Day 27, respectively
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mice challenged by the B16F10 cells as is shown in
Figure 3B.
Compared with the immunized mice that were chal-
lenged by the B16F10 cells, only 1 out of the 6 mice de-
veloped tumor after the mice were challenged by the
B16F10/shZEB1 cells, and the measurable tumors were
not detected in other 5 mice until 60 days into the ob-
servation, but the most powerful antimelanoma efficacy
was found in the immunized mice that were challenged
by the B16F10/miR200c cells, which was reflected in 1
out of the 6 mice developing the smaller tumor, the lon-
ger survival time, the lower tumor metastasis counts and
the weaker pathological changes in murine lung than
those of other mice that were shown in Figure 3. The re-
sults from the tumor area and tumor metastasis counts
in lungs suggested that the synergism antitumor efficacy
was found in mice immunized with the tumor vaccine
B16F10/GPI-IL-21 in combination with either overexpres-
sion of miR200c or knockdown of ZEB1 in B16F10 cells.
EMT-related molecular expression in tumor tissues in
mice
To analyze the mechanisms of the overexpression of
miR200c or knockdown of ZEB1 for reinforcing the anti-
melanoma efficacy of the tumor vaccine B16F10/GPI-IL-Figure 4 EMT-related molecular expression detected by western blot
blot in B16F10 WT cells, B16F10/shZEB1 cells, B16F10/GPI-IL-21cells, and B1
intensity of molecular expression and the detection of the band intensities21, we detected the EMT-related molecular expression
in tumor tissues from the immunized mice. It is known
that EMT is a process associated with many factors
[12,17], of which TGF-β, Vimentin, ZEB-1, SMAD-7, E-
cadherin and N-cadherin molecules are closely associ-
ated with the typical phenotype change of EMT in the
process of tumor cell growth [22,27]. The representative
results in Figure 4A showed these molecular expression
in tumor tissues detected by western blotting.
It was found that the expression of TGF-β, Vimentin,
ZEB-1 and N-Cad was significantly decreased in tumor
tissues from the B16F10/GPI-IL-21 vaccination of mice
challenged by the B16F10/miR200c cells compared with
other groups, whereas the expression of SMAD-7 and
E-cadherin was significantly increased in tumor tissues,
and the differences were statistically significant as are
shown in Figures 4B-C. Consistent with the results of
western blotting, the immunohistochemical analysis of
tumor tissue sections showed that the molecular expres-
sion of TGF-β, Vimentin, ZEB-1 and N-cadherin was
also reduced in tumor tissues, and that the SMAD-7
and E-cadherin expression was remarkably increased in
the B16F10/GPI-IL-21 vaccination of mice that were
then challenged by the B16F10/miR200c cells compared
with B16F10/WT cells (Figure 5). From these results, we
concluded that the B16F10/GPI-IL-21 vaccination of. (A) The EMT-related molecular expression was examined by western
6F10/miR200c cells, respectively. (B, C) The statistical analysis of relative
are all within the same dynamic range.
Figure 5 EMT-related molecular changes detected by immunohistochemistry assay. (A, B) The EMT-related molecular expression was
examined by immunohistochemistry assay in B16F10 WT cells, B16F10/shZEB1 cells, B16F10/GPI-IL-21cells, and B16F10/miR200c cells, respectively.
The statistical analysis of relative intensity of molecular expression were shown in histograms.
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lecular expression in tumor tissues from the mice chal-
lenged by the B16F10/miR200c cells or the B16F10/
shZEB1 cells that increased miR200c expression or
decreased ZEB1 expression. The high expression of
SMAD-7 and E-cadherin, accompanied with low ex-
pression of TGF-β, Vimentin, ZEB-1 and N-cadherin,
may inhibit the EMT of B16F10 cells.Discussion
In the present study, our goal was to use a tumor vac-
cine B16F10/GPI-IL-21 in combination with regulation
expression of miR200c and ZEB1 against melanoma, an
aggressive skin cancer that there is no cure in advanced
stages until now. We first selected the B16F10/GPI-IL-
21 vaccine as an immune agonist to induce the mice to
generate a strong immune responses such as increase of
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crease of TGF-β level and enhancement of the spleno-
cyte cytotoxic activity in the immunized mice. Since the
malignant melanocytes can spread to distant locations
and cause metastasis this process is involved in the EMT
of melanoma in which miR200c and ZEB1 may be down-
regulation or upregulation. Therefore, we next combined
the tumor vaccine B16F10/GPI-IL-21 with miR200c over-
expression or ZEB1 knockdown in B16F10 cells to test the
novel strategy for optimizing the therapeutic management
of melanoma growth and metastasis in mice.
In an experimental model of melanoma growth and
metastases, we found the tumor growth was significantly
inhibited in the B16F10/GPI-IL-21 vaccination of mice
that were then challenged by the B16F10/miR200c cells,
which was reflected in weaker tumorigenicity, smaller
tumor volumes, lower lung metastases and longer sur-
vival in melanoma bearing mice than those of mice that
were challenged by the B16F10 cells (Figure 3). Even
though, the B16F10/GPI-IL-21 vaccination of mice chal-
lenged by the B16F10/shZEB1 cells or B16F10/GPI-IL-
21 cells also indicated antitumor efficacy this efficacy
was remarkably found in B16F10/miR200c cell group.
To address the functional significance of the miR200c
overexpression or ZEB1 knockdown in B16F10 cells, we
tested the EMT-related molecular expression in tumor tis-
sues. It is known that the increased expression of TGF-β,
Vimentin, ZEB-1and N-cadherin could promote EMT
progression of tumor cells [27-30], whereas the decreased
expression of SMAD-7 and E-cadherin could inhibit the
EMT progression [31,32]. It has been observed that the
expression of TGF-β, Vimentin, ZEB-1 and N-cadherin
detected by western blot was markedly decreased, accom-
panied with increased expression of SMAD-7 and E-
cadherin in the B16F10/GPI-IL-21 vaccination of mice
challenged by the B16F10/miR200c cells. Consistent with
the western blot results, the expression of TGF-β, Vimen-
tin, ZEB-1 and N-cadherin detected by immunohisto-
chemistry assay was also remarkably decreased, whereas
the expression of SMAD-7 and E-cadherin was notably
increased in the tumor tissues. On the basis of these
findings, we speculated that enforced miR-200c expres-
sion in melanoma B16F10 cells profoundly impairs cell
tumorigenicity and phenotype change of EMT along with
significantly decreased expression of TGF-β, Vimentin,
ZEB-1and N-cadherin. Since the regulation of ZEB1 ex-
pression is also associated with the cell’s EMT, the tumor
metastases and change of molecular expression above-
mentioned were investigated in vivo experiment as well.
We found that ZEB1 knockdown may correspond to re-
duced tumorigenicity and EMT change of B16F10 cells as
well as melanoma metastases in vivo mouse model.
Several molecules, for example, IFN-gamma, SMAD-7
and E-cadherin confer inhibition of EMT to B16F10 cells[28,29,33,34]. It was reported that IFN-γ and TGF-β have
opposite effects on diverse cellular functions. IFN-γ in-
hibits the TGF-β-induced phosphorylation of SMAD-3
and the accumulation of SMAD-3 in the nucleus, and the
activation of TGF-β-responsive genes [33-35]. Based on
the experiment results that the serum IFN-γ was in-
creased, and TGF-β was decreased as well as SMAD-7
expression was increased in tumor tissues from the immu-
nized mice, we presumed that IFN-γ may specifically in-
hibit an early step in the TGF-β-induced activation of
SMAD-3 through a receptor serine kinase that phosphor-
ylates and activates the transcription factors SMAD-2 and
SMAD-3. Since IFN-γ also induces the expression of
SMAD-7, an antagonistic SMAD, which prevents the
interaction of SMAD-3 with the TGF-β receptor [33],
therefore, we guess the increased SMAD-7 in tumor cells
may bind to the TGF-β-receptor complex, preventing its
interaction with, and phosphorylation of SMAD-3 [36,37],
which may result in inhibition of melanoma growth and
metastasis in mice. In addition, miR200c overexpression
or ZEB1 knockdown is most likely to suppress tumor ma-
lignancy by enhancing E-cadherin expression (Figures 4
and 5A) and/or by inhibiting signals that suppress
E-cadherin function.
Conclusions
Our data represents the first attempt to improve the
tumor vaccine B16F10/GPI-IL-21 efficacy in combin-
ation with miR200c overexpression or ZEB1 knockdown
in B16F10 cells. This efficacy resulted in inhibition of
melanoma growth and metastasis in melanoma bearing
mouse model. The tumor vaccine B16F10/GPI-IL-21 im-
proves IFN-γ secretion and induces antitumor immune
responses. Regulation expression of miR200c and ZEB1
in B16F10 cells positively led to expression changes of
TGF-β, Vimentin, ZEB-1, N-cadherin, SMAD-7 and E-
cadherin in tumor tissues from the B16F10/GPI-IL-21
vaccination of mice, which are correlated with progres-
sion of EMT of B16F10 cells as well as influence of
melanoma growth and metastasis in mice. These find-
ings encourage the exploitation of these combined strat-
egies in clinic trials.
Abbreviations
EMT: Epithelial to mesenchymal transition; GPI: Glycosylpho sphatidylinositol;
miR200c: microRNA-200c; ZEB1: Zinc-finger E-box binding homeobox 1;
CFSE: Carboxyfluoroscein diacetate succinimidyl ester; FACS:
Fluorescence-assisted cell; ELISPOT: Enzyme-linked immunospot;
TGF-β: Transforming growth factor-β; IFN-γ: Interferonγ; TNF-α: Tumor
necrosis factor α; IL-4: Interleukin 4.
Competing interests
The authors declared that they have no competing interests.
Authors’ contributions
XW, FZ and XH carried out the experiments described in the manuscripts,
developed the technique described in the manuscript, and participated in
the writing of the manuscript. JW, HZ, FS, YZ, KC and JS participated in most
Wang et al. Journal of Translational Medicine 2014, 12:68 Page 10 of 11
http://www.translational-medicine.com/content/12/1/68of the experiments. JD and FZ contributed to the design of the experiments
and contributed to the writing of the manuscript. All authors have read and
approved the final manuscript.
Authors’ information
Xiaoying Wang, Xiangfeng He and Fengshu Zhao are co-authors.
Acknowledgements
We thank Dengyu Cheng, Wenhu Cao, and Yurong Liu for their help with
short hairpin RNA sequence design and transduction of lentivirus miR-200c.
Financial support
This work was supported by the National Natural Science Foundation of
China (No. 81071769, No. 81202372), and in part by the 973 National Nature
Science Foundation of People’s Republic of China (2011CB933500).
Author details
1Department of Pathogenic Biology and Immunology of Medical School,
Southeast University, Nanjing 210009, China. 2Department of Medical
Oncology, Affiliated Tumor Hospital of Nantong University, Nantong 226361,
China. 3Department of Gynecology & Obstetrics, Zhongda Hospital, Medical
School, Southeast University, Nanjing 210009, China. 4Department of
Oncology, Zhongda Hospital, Southeast University, Nanjing 210009, China.
Received: 19 January 2014 Accepted: 4 March 2014
Published: 14 March 2014
References
1. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Morrison SJ:
Phenotypic heterogeneity among tumorigenic melanoma cells from
patients that is reversible and not hierarchically organized. Cancer Cell
2010, 18:510–523.
2. Romano S, Staibano S, Greco A, Brunetti A, Nappo G, llardi G, Martinelli R,
Sorrentino A, Di Pace A, Mascolo M, Bisogni R, Scalvenzi M, Alfano B,
Romano MF: FK506 binding protein 51 positively regulates melanoma
stemness and metastatic potential. Cell Death Dis 2013, 4:e578.
3. Farolfi A, Ridolfi L, Guidoboni M, Nicoletti SV, Piciucchi S, Valmorri L,
Costantini M, Scarpi E, Amadori D, Ridolfi R: Ipilimumab in advanced
melanoma: reports of long-lasting responses. Melanoma Res 2012,
22:263–270.
4. Drake CG, Lipson EJ, Brahmer JR: Breathing new life into immunotherapy:
review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014,
11:24–37.
5. Kwek SS, Cha E, Fong L: Unmasking the immune recognition of prostate
cancer with CTLA4 blockade. Nat Rev Cancer 2012, 12:289–297.
6. Naghibalhossaini F, Yoder AD, Tobi M, Stammers CP: Evolution of a
tumorigenic property conferred by glycophosphatidyl-inositolmembrane
anchors of carcinoembryonic antigen gene family members during the
primate radiation. Mol Biol Cell 2007, 18:1366–1374.
7. Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK,
Mouritzen U, Hansen LT, Skak K, Lundsgaard D, Frederiksen KS, Kristjansen
PE, McArthur G: Clinical and biological efficacy of recombinant human
interleukin-21 in patients with stage IV malignant melanoma without
prior treatment: a phase IIa trial. Clin Cancer Res 2009, 15:2123–2129.
8. Davis JM, Harris MP, Davidson NE, Kobrin BJ, Jaffee EM, Emens LA: Cost-
effective manufacture of an allogeneic GM-CSF-secreting breast tumor
vaccine in an academic cGMP facility. Cytotherapy 2005, 7:46–56.
9. Shu S, Cochran AJ, Huang RR, Morton DL, Maecker HT: Immune responses
in the draining lymph nodes against cancer: implications for
immunotherapy. Cancer Metastasis Rev 2006, 25:233–242.
10. Zhao F, Dou J, Wang J, Chu L, Tang Q, Wang Y, Li Y, Cao M, Hu W, Hu K,
Feng He X, Gu N: Investigation on the anti-tumor efficacy by expression
of GPI-anchored mIL-21 on the surface of B16F10 cells in C57BL/6 mice.
Immunobiology 2010, 215:89–100.
11. Zhao F, Dou J, He XF, Wang J, Chu L, Hu W, Yu F, Hu K, Wu Y, Gu N:
Enhancing therapy of B16F10 melanoma efficacy through tumor vaccine
expressing GPI-anchored IL-21 and secreting GM-CSF in mouse model.
Vaccine 2010, 28:2846–2852.
12. Ulrike B, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S,
Brabletz T: A reciprocal repression between ZEB1 and members of themiR-200 family promotes EMT and invasion in cancer cells. EMBO Rep
2008, 9:582–589.
13. Bracken CP, Gregory PA, Kolesnikoff N: A double-negative feedback loop
between ZEB1-SIP1 and the microRNA-200 family regulates
epithelial- mesenchymal transition. Cancer Res 2008, 68:7846–7854.
14. Chen D, Wang J, Zhang Y, Chen J, Yang C, Cao W, Zhang H, Liu Y, Dou J:
Effect of down-regulated transcriptional repressor ZEB1 on the
epithelial-mesenchymal transition of ovarian cancer cells. Int J Gynecol
Cancer 2013, 23:1357–1366.
15. Chen D, Zhang Y, Wang J, Chen J, Yang C, Cai K, Wang X, Shi F, Dou J:
MicroRNA-200c overexpression inhibits tumorigenicity and metastasis
of CD117+CD44+ovarian cancer stem cells by regulating
epithelial-mesenchymal transition. J Ovarian Res 2013, 6:50.
16. He X, Wang J, Zhao F, Yu F, Chen D, Cai K, Yang C, Chen J, Dou J:
Antitumor efficacy of viable tumor vaccine modified by heterogenetic
ESAT-6 antigen and cytokine IL-21 in melanomatous mouse. Immune Res
2012, 53:240–249.
17. Bendoraite A, Knouf EC, Garg KS: Regulation of miR-200 family microRNAs
and ZEB transcription factors in ovarian cancer: Evidence supporting a
mesothelial-to-epithelial transition. Gynecol Oncol 2010, 116:117–125.
18. Dou J, He XF, Cao WH, Zhao FS, Wang XY, Liu YR, Wang J: Overexpression
of microRNA-200c in CD44+CD133+ CSCS inhibits the cellular migratory
and invasion as well as tumorigenicity in mice. Cell Mol Biol 2013,
59:OL1861–OL1868.
19. Wang J, Zhou DD, He XF, Wang Y, Hu W, Jiang L, Dou J: Effect of
downregulated β-catenin on cell proliferative activity, the sensitivity to
chemotherapy drugs and tumorigenicity of ovarian cancer cells. Cell Mol
Biol 2011, 57:OL1606–OL1613.
20. Zhang H, Wang J, Cai K, Jiang L, Zhou D, Yang C, Chen J, Chen D, Dou J:
Downregulation of gene MDR1 by shRNA to reverse multidrug- resistance
of ovarian cancer A2780 cells. J Cancer Res Ther 2012, 8:226–231.
21. Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post
MD, Lu X, Broaddus RR, Spillman MA, Richer JK: Restoration of miR-200c to
ovarian cancer reduces tumor burden and increases sensitivity to
paclitaxel. Mol Cancer Ther 2012, 11:2556–2565.
22. Liu SJ, Tetzlaff MT, Cui R, Xu X: miR-200c inhibits melanoma progression
and drug resistance through down-regulation of Bmi-1. Am J Pathol 2012,
181:1823–1835.
23. Rosenberg SA, Sherry RM, Morton KE: Tumor progression can occur
despite the induction of very high levels of self/tumor antigen-specific
CD8+ T cells in patients with melanoma. J Immunol 2005, 175:6169–6176.
24. Dou J, Wu Y, Wang J, Zhao F, Chu L, Liu C, Wen P, Hu W, Hu K, He XF,
Gu N: Eliciting protective immune responses against murine myeloma
challenge in lymphopenia mice through adoptive transfer of tumor
antigen-specific lymphocytes and immunization of tumor vaccine
secreting mIL-21. Cancer Gene Ther 2010, 17:675–683.
25. Hervé L, Michèle F, Sylvie G: A novel flow cytometric assay for
quantitation and multiparametric characterization of cell-mediated
cytotoxicity. J Immunol Methods 2001, 253:177–187.
26. Yang X, Lin X, Zhong X, Kaur S, Li N, Liang S, Lassus H, Wang L, Katsaros D,
Montone K, Zhao X, Zhang Y, Bützow R, Coukos G, Zhang L: Double-
negative feedback loop between reprogramming factor LIN28 and
microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer
stem cells. Cancer 2010, 70:9463–9472.
27. Jukic DM, Rao UN, Kelly L, Skaf JS, Drogowski LM, Kirkwood JM, Panelli MC:
Microrna profiling analysis of differences between the melanoma of
young adults and older adults. J Transl Med 2010, 8:27.
28. Bierie B, Moses HL: Tumour microenvironment: TGF beta: the molecular
Jekyll and Hyde of cancer. Nat Rev Cancer 2006, 6:506–520.
29. Massague’ J: TGF in cancer. Cell 2008, 134:215–230.
30. Qu X, Shen L, Zheng Y, Cui Y, Feng Z, Liu F, Liu J: A signal transduction
pathway from TGF-β1 to SKP2 via Akt1 and c-Myc and its correlation with
progression in human melanoma. J Invest Dermatol 2014, 134:159–167.
31. Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal
transitions in development and disease. Cell 2009, 139:871–890.
32. Liu S, Tetzlaff MT, Liu A, Liegl-Atzwanger B, Guo J, Xu X: Loss of
microRNA-205 expression is associated with melanoma progression.
Lab Invest 2012, 92:1084–1096.
33. Ulloa L, Doody J, Massagué J: Inhibition of transforming growth
factor-beta/SMAD signalling by the interferon-gamma/STAT pathway.
Nature 1999, 397:710–713.
Wang et al. Journal of Translational Medicine 2014, 12:68 Page 11 of 11
http://www.translational-medicine.com/content/12/1/6834. Hirano T, Satow R, Kato A, Tamura M, Murayama Y, Saya H, Kojima H,
Nagano T, Okabe T, Fukami K: Identification of novel small compounds
that restore E-cadherin expression and inhibit tumor cell motility and
invasiveness. Biochem Pharmacol 2013, 86:1419–1429.
35. Wen FQ, Liu X, Kobayashi T, Abe S, Fang Q, Kohyama T, Ertl R, Terasaki Y,
Manouilova L, Rennard SI: Interferon-gamma inhibits transforming growth
factor-beta production in human airway epithelial cells by targeting
Smads. Am J Respir Cell Mol Biol 2004, 30:816–822.
36. Weng H, Mertens PR, Gressner AM, Dooley S: IFN-gamma abrogates
profibrogenic TGF-beta signaling in liver by targeting expression of
inhibitory and receptor Smads. J Hepatol 2007, 46:295–303.
37. Kuga H, Morisaki T, Nakamura K, Onishi H, Noshiro H, Uchiyama A, Tanaka
M, Katano M: Interferon-gamma suppresses transforming growth
factor-beta-induced invasion of gastric carcinoma cells through
cross-talk of Smad pathway in a three-dimensional culture model.
Oncogene 2003, 22:7838–7847.
doi:10.1186/1479-5876-12-68
Cite this article as: Wang et al.: Regulation gene expression of miR200c
and ZEB1 positively enhances effect of tumor vaccine B16F10/GPI-IL-21
on inhibition of melanoma growth and metastasis. Journal of
Translational Medicine 2014 12:68.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
